Summary
Management of BOS complicating LT is difficult because no treatment strategies have been proven to influence survival or long-term outcome ( Table 6 ). For patients failing aggressive medical therapy, retransplantation is an option, but given the limited number of donor organs, the ethics and role of retransplantation in this context are controversial. Ultimately, a greater understanding of the pathogenesis of BOS may allow development of novel therapeutic strategies that may improve outcome.
This work was supported, in part, by grants from the NIH (HL04493 to JAB; HL03906 to MPK; P01HL67665 to MPK and RMS; and CA87879, P50CA90388, and HL66027 to RMS). JAB is a recipient of the ALA Research Grant Award, RG-019-B.
John Belperio, M.D., Division of Pulmonary and Critical Care Medicine, University of California at Los Angeles, David Geffen School of Medicine, 900 Veteran Ave., 14-154 Warren Hall, Box 711922, Los Angeles, CA 90024-1922. E-mail: jbelperio@mednet.ucla.edu.
Semin Respir Crit Care Med. 2003;24(5) © 2003 Thieme Medical Publishers
Comments